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Abstract
Three novel 63 cardiac myosin heavy chain (MHC) gene mis-
sense mutations, Phe513Cys, Gly716Arg, and Arg719Trp,
which cause familial hypertrophic cardiomyopathy (FHC) are
described. One mutation in exon 15 (Phe513Cys) does not
alter the charge of the encoded amino acid, and affected family
members have a near normal life expectancy. The Gly716Arg
mutation (exon 19; charge change of +1) causes FHC in three
family members, one of whom underwent transplantation for
heart failure. The Arg719Trp mutation (exon 19; charge
change of -1) was found in four unrelated FHC families with a
high incidence of premature death and an average life expec-
tancy in affected individuals of 38 yr. A comparable high fre-
quency of disease-related deaths in four families with the
Arg719Trp mutation suggests that this specific gene defect di-
rectly accounts for the observed malignant phenotype. Further,
the significantly different life expectancies associated with the
Arg719Trp vs. Phe513Cys mutation (P < 0.001) support the
hypothesis that mutations which alter the charge of the en-
coded amino acid affect survival more significantly than those
that produce a conservative amino acid change. (J. Clin. Invest.
1994. 93:280-285.) Key words: cardiac hypertrophy - mis-
sense * survival * sudden death
Introduction
Molecular genetic studies have begun to decipher the broad
clinical spectrum of familial hypertrophic cardiomyopathy
(FHC).' Chromosomes 1 (1), 11 (2), 14 (3), and 15 (4) have
been demonstrated to contain disease loci that cause FHC, but
specific mutations have only been identified in the A cardiac
myosin heavy chain (MHC) gene on chromosome 14. Allelic
heterogeneity further contributes to the complexity of the ge-
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1. Abbreviations used in this paper: FHC, familial hypertrophic cardio-
myopathy; MHC, myosin heavy chain.
netic basis of FHC. Many different missense mutations have
been identified in the head or head/rod junction of the / car-
diac MHC gene in families with this disorder.
Identification of the full complement of /3 cardiac MHC
gene mutations that cause FHC may help in both the elucida-
tion of the pathophysiology of this disorder and the assessment
of prognosis. Analyses of genotype and phenotype may in par-
ticular provide insights into the molecular basis for cardiac
dysfunction in this condition. Studies have detected little corre-
lation between the morphologic characteristics ofthe hypertro-
phic phenotype seen in four different a cardiac MHC gene
mutations (5), suggesting that the extent and distribution of
the cardiac hypertrophy observed in affected individuals re-
flects the interactions of other genes and/or environmental
factors. In contrast, there is recent evidence that genotype can
account for the variable patient outcomes observed in different
families with FHC. Different missense mutations within the /3
cardiac MHC gene appear to be associated with different life
expectancies in affected individuals (6). Two mutations have
been identified (Val606Met [6] and Leu9O8Val; [7]) that pro-
duce a conservative change of the encoded amino acid. The
prognosis of individuals with these mutations appears better
than that observed in individuals with a /3 cardiac MHC gene
mutation that encodes an amino acid with a different charge.
To further elucidate those features of / cardiac MHC gene
mutations that impact on the clinical manifestations of FHC,
we have studied additional families. Three novel mutations
have been identified in six unrelated families. Analyses of clini-
cal data were informative for two mutations. We report a novel
conservative mutation (Phe513Cys) that has little effect on
patient survival and a nonconservative mutation (Arg719Trp)
that is associated with a significant reduction in life expectancy.
Methods
Clinical evaluation. Consent was obtained in accordance with the local
institutional review committees for human subject investigations.
Clinical, electrocardiographic and echocardiographic assessments of
six families were performed as described previously (3, 8). The diagno-
sis ofhypertrophic cardiomyopathy was based on the demonstration of
unexplained left, right, or biventricular hypertrophy. Blood was ob-
tained from all family members for genetic analyses.
Clinical records and family history were obtained to determine the
number of disease-related deaths, and the age at death or current age
for all affected individuals in each family. For Kaplan-Meier survival
curves, individuals who were resuscitated from cardiac arrest were
scored as deceased at the age of their event. Kaplan-Meier product
limit survival curves were produced as described (6).
Detection of mutations. Lymphocytes isolated from peripheral
blood samples were used to establish a transformed cell line with Ep-
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stein-Barr virus as described previously (3). [ cardiac MHC gene or
mRNA sequences were amplified from a proband's transformed lym-
phocytes by sequential rounds of PCR (9). Amplified sequences were
hybridized to RNA probes transcribed from a normal gene and RNase
A protection assays performed as described (6). Analyses were limited
to sequences encoding amino acid residues 1-1,080, which were exam-
ined using both sense and antisense riboprobes. Amplified sequences
that yielded abnormal RNA cleavage patterns were reanalyzed with
new DNA or mRNA isolates to exclude artifacts arising from PCR.
DNA obtained from probands in two families ( 120 and 134) were
scanned for mutations in exon 19 and 20 by chemical cleavage as de-
scribed elsewhere (10, 11 ). These exons were amplified together and
heteroduplexes were formed by a denaturing and reannealing reaction
between the PCR template and both sense and antisense radiolabelled
probes transcribed from a normal gene. The heteroduplexes were modi-
fied separately with hydroxylamine and osmium tetroxide, and the
modified products were cleaved with piperidine. Products were re-
solved by electrophoresis in an 8% polyacrylamide gel.
Mutations identified by RNase protection assays or chemical cleav-
age were subjected to dideoxy nucleotide sequence analysis. Where
possible, the nucleotide change identified by sequencing was indepen-
dently confirmed by demonstration ofa predicted change in restriction
enzyme site or by chemical cleavage ofthe exon containing a mutation.
Amino acid sequences were deduced from DNA sequences. Nucleotide
and amino acid residues are numbered according to Jaenicke ( 12 ). The
following primers were used to amplify exons 15 and 19:
Forward (1SF): ACTCACACCCACTTTCTGACTGCTC
Reverse (15R): GAATTCAGGTGGTAAGGCCAAAGAG
Forward (I9F): CTCACAGACTCCTCCTACTTCCTTC
Reverse (19R): GCCTGGCTCCCCCTGTTCTATGAGC
Family AX
II
III bLL
IV ( 0[
12 ;
V |
Familv AZ
I1
111
Family Al
II
11
. 2
III 5
,. 2
Figure 1. Pedigrees of three FHC families. Symbols denote sex and
disease-status: box, male; circle, female; solid, affected; clear, unaf-
fected; speckled, unknown; slashed, deceased. Individuals identified
with a pedigree number were clinically and genetically studied.
Results
Clinical results. The pedigrees ofthree FHC families (AX, AZ,
and Al) are shown in Fig. 1. All affected members had typical
clinical features of this disorder (Table I). Family AX is of
Japanese ancestry. Of 11 affected individuals 3 have died; in 1
death was disease-related; in 2 death was noncardiac and oc-
cuffed in the 8th decade. Family AZ resides in Italy. Three
affected individuals have been identified and two (II-1 and
III- 1 ) have developed progressive left ventricular wall thinning
with systolic dysfunction. Individual II-1 underwent cardiac
transplantaton for intractable heart failure at age 42. The bi-
ventricular weight of the explanted heart was 400 g and coro-
nary anatomy was normal. Histologic examination demon-
strated interstitial fibrosis (less than 1.5 cm in length) and
myocyte hypertrophy. Family Al is a small family from the
UK. Two affected individuals are alive, one ofwhom was resus-
citated from sudden death at age 19.
Clinical studies of three other FHC families ( 101, 120, and
134) have been previously reported (8, 13, 14). In addition to
the typical signs and symptoms of FHC found in affected
members of these families, a high incidence of sudden death
and disease-related death has been observed. Of 28 affected
individuals in family 101, 19 died prematurely (before age 58);
death was sudden in 10 individuals and disease-related in 9
individuals. Of 7 affected individuals from family 120, sudden
death occurred in 2 and disease-related death occurred in 1.
Death occurred in 12 of 23 affected members of family 134; in
10, death was sudden; in 2, death was disease-related; one sur-
vivor in this family was resuscitated from sudden cardiac death
at age 15.
Mutation identification. The [B cardiac MHC sequences ofa
proband from families AX, AZ, Al, and 101 were screened for
missense mutations using RNase protection assays as described
previously (6, 9). Because most ,B cardiac MHC gene muta-
tions have been identified in the amino terminal half of the
gene (6), sequences encoding amino acid residues 1-1,080
were analyzed. PCR-amplified sequences that produced un-
usual RNase protection cleavage products were subcloned and
their nucleotide sequences determined. The same abnormal
product was observed in RNase protetion assays of probands
from families Al and 101, suggesting that they shared the same
1B cardiac MHC gene mutation. Nucleotide sequence analyses
confirmed that in the probands from families AI and 120 the
cytosine at position 2241 (exon 19) has been mutated to a
thymine residue (Fig. 2 A and data not shown).
The C224 1 T transition abolishes an MspI site found in un-
affected individuals (Fig. 3 A, Arg7 l9Trp) and is also identified
by chemical cleavage of PCR-amplified exon 19 and 20 DNA
(data not shown). These methods permit independent confir-
mation of genotypes identified by RNase protection assays.
Restriction enzyme digestion or chemical cleavage ofPCR-am-
plified exon 19 sequences were used to study all affected indi-
viduals in families Al and 101 and in two additional FHC
families ( 120 and 134). All members of families Al, 101, 120,
and 134 with clinical evidence of FHC were demonstrated to
have the C224 1T mutation.
A second mutation in exon 19 was identified by RNase
protection assay. A transition (guanine 2232 to adenine, Fig. 2
B) was identified in the proband of family AZ. This mutation
creates a novel SfcI restriction enzyme site (Fig. 3 B,
Gly7 1 6Arg). PCR amplification of exon 19 of the ,B cardiac
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Table I. Clinical Features ofFHC in Affected Individualsfrom Three Families
Clinical symptoms Electrocardiogram 2-D echocardiogram
Chest LVH MAX LA
Subject Age/sex pain Dyspnea Syncope BBB ABN Q +/- ST LVWT RVH SAM SIZE
AX III-2 72 M - III - - - - 14 - - 38
AX III-4 65 M - III - - - + 22 - + 54
AX III-6 57 M - I - - - + 17 - + 45
AX III-7 54 F - III - - - + 17 - - 32
AX III-9 75 M - II - - - - 19 - - 40
AX III-I1 72 M - I - - + + 22 - - 33
AX IV-2 40 M - I - - + - 17 - - 43
AXV-1* 8 M - I - - - - 9* - - 20
AZ II-1 43 M - III - L - - 25 - - 60
AZ III-1 22 M - II + L - - 17 - - 55
AZ III-2 16 M - I - - - + 20 - - 44
AI II-1 58 M - I - B - - 21 - - 50
AI III-2 22 F - I + B - - 26 - - 58
The degree of dyspnea present was based on the New York Heart Association functional classification. BBB denotes bundle-branch block (R,
right; L, left; B, bifasicular); ABN Q, abnormal Q wave; LVH +/- ST, left ventricular hypertrophy with voltage criteria and/or repolarization
changes. Max LVWT, maximal thickness ofthe left ventricular wall (mm); RVH, right ventricular hypertrophy; SAM, systolic anterior motion
of the mitral valve, LA, left atrial size (mm). * FHC was diagnosed in individual AX V- I (age 8) based on an increased LVWT for his body
surface area of 1.08 m2.
MHC gene from all members of family AZ demonstrated this
SfcI site only in those individuals with FHC.
RNase protection assays of the proband from family AX
identified a mutation in exon 15 that changes the thymine at
position 1624 to a guanine (Fig. 2 C). Since this transversion
does not effect a restriction enzyme site, all family members
were studied with RNase protection assays. Only clinically af-
fected individuals were found to have two novel fragments re-
sulting from cleavage ofthe normal 171 -bp product into prod-
ucts of sizes 130 and 41 bp (Fig. 3 C).
The evidence that these nucleotide changes accounts for
FHC is based on three observations. First, each nucleotide
change alters an encoded amino acid. The C224 1T mutation in
families AlI, 101, 120, and 134 encodes an Arg7 1 9Trp change;
the G2232A mutation in family AZ encodes a Gly716Arg
change; the T1624G mutation in family AX encodes a
Phe5 1 3Cys change. Two of these missense mutations are non-
conservative and alter the charge (Arg7l9Trp, -1 and
Gly7 l6Arg, + 1) of the encoded amino acid. Second, each of
these missense mutations alters an amino acid that has been
conserved in all mammalian myosin molecules studied (data
not shown). The PheS 1 3Cys mutation alters a myosin heavy
chain residue that has been stringently conserved in all verte-
brates. Third, these mutations have not been found in analyses
of more than 200 normal chromosomes. Fourth, there is com-
plete concordance between clinical status and genotype in each
family.
Survival analyses. To define the natural history of hyper-
trophic cardiomyopathy due to each of these missense muta-
tions, we compared the survival of affected individuals from
each family. Too few individuals with the Gly7 16Arg mutation
were present in Family AZ to construct meaningful Kaplan-
Meier survival curves. However we note that one of three af-
fected individuals has required cardiac transplantation for pro-
gressive left ventricular wall thinning associated with intract-
able heart failure. Four unrelated families with FHC resulting
from an Arg7l9Tr mutation were identified. Survival of af-
fected individuals in each of these families was similar and
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Figure 4. Kaplan-Meier product-limit curves for the survival of indi-
viduals bearing the Arg7 1 9Trp or Phe5 1 3Cys mutation. Data from
four unrelated families with the Arg7 19Trp mutation are combined,
as no differences were detected between these families. A significant
difference (P < 0.001 ) in life expectancy was observed in individuals
with the Arg7 l9Trp vs. the PheS 1 3Cys mutation.
averaged only 38 yr. In contrast, survival was near normal in
the 11 affected individuals from family AX with the conserva-
tive Phe5 1 3Cys mutation. Fig. 4 demonstrates the significantly
different survival (P < .001) associated with FHC due to the
Arg7 1 9Trp mutation vs. the Phe5 1 3Cys mutation. Life expec-
tancy associated with the Phe5 1 3Cys is comparable to that seen
in other conservative cardiac MHC gene mutations (6). The
Arg7 1 9Trp mutation portends a survival that is comparable to
that seen in FHC due to an Arg4O3Gln mutation; both muta-
tions are associated with a particularly poor prognosis.44- 41bp
Figure 3. A representation of techniques used to genotype family
members for d cardiac MHC gene mutations. (A) Arg7l9Trp (exon
19): A 200-bp fragment of the cardiac MHC gene was amplified
using primers numbered B19F and BI9R (Methods) and digested
with MspI. Sequence from clinically unaffected individuals (P) gen-
erates fragments of 144 and 56 bp; individuals with the Arg7 l9Trp
mutation lack the MspI site on one allele, resulting in the 200-bp as
well as normal fragments. (B) Gly7 l6Arg (exon 19): A 500-bp frag-
ment of the d cardiac MHC cDNA was amplified as using primers
1925F and 2424R (6) and digested with SfcI. Analysis ofcDNA from
an unaffected individual (P) yields products of sizes 274 and 226 bp.
DNA from individuals with the Gly7 16Arg mutation have an addi-
tional SfcI site that cleaves the 226-bp fragment into fragments sized
Discussion
We report three previously unidentified cardiac MHC gene
mutations that cause FHC in six families. Two of these muta-
at 196 and 30 bp (not visible). (C) Phe5 1 3Cys (exon 15) is detected
by RNase protection assays. Amplified DNA is hybridized to a 3p_
labeled RNA probe derived from cardiac MHC gene sequences (6).
RNase A digests hybrid molecules containing mismatched base pairs.
Unaffected individuals (P) contain the 17 1-bp fragment, which is
cleaved into 130- and 4 l-bp fragments in affected individuals.
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tions (Arg719Trp and Gly716Arg) change the charge of the
encoded amino acid, while one (PheS 13Cys) is a conservative
mutation. Affected individuals from four families bearing the
Arg719Trp mutation have a marked reduction in life expec-
tancy, while affected individuals with the PheS 13Cys mutation
have a near normal survival. These analyses add to the growing
body of information regarding the effect that a particular 1
cardiac MHC gene mutation has on clinical outcome in FHC.
15 1 cardiac MHC missense mutations that cause FHC
have been identified (Fig. 5). A wide range in the distribution
and severity of hypertrophy has been observed in affected indi-
viduals with the same mutation (3, 5, Table I, and our unpub-
lished data) suggesting a multifactorial etiology to the morpho-
logic features of this disorder. In contrast, analyses of the natu-
ral history of FHC in large kindreds and in unrelated families
with a common mutation demonstrate that genotype can sub-
stantially influence survival. We suggest that ,B cardiac MHC
missense mutations can be divided into three groups (Fig. 5):
benign (B) or those associated with near normal life expec-
tancy, malignant (M) or those which significantly reduce life
expectancy, and intermediate (I) or those with a moderate ef-
fect on life expectancy.
Three benign mutations have been identified, located in the
head region (Phe513Cys, exon 15; Val606Met, exon 16 [6]) or
in the head/rod junction (Leu9O8Val, exon 23 [7, 16]). Each
of these is a conservative mutation, suggesting that the lack of
charge change may in part account for the good prognosis asso-
ciated with these mutations. Regional localization may also
contribute to a benign phenotype. None ofthe mutations char-
acterized as malignant occur in the head/rod junction and the
sole mutation identified in the rod (a 3' deletion [17] ) produces
a strikingly late onset ofdisease. Collectively, these data suggest
that mutations which arise within the head/rod or rod region
are more likely to be benign or may be clinically silent.
Significant premature mortality accompanies three muta-
tions: Arg4O3Gln (exon 13 [15]), Arg453Cys (exon 14 [6] ), or
Arg7l9Trp (exon 19). In contradistinction to that observed in
myosin mutations of the nematode (18), there appears to be
little clustering of malignant mutations within the head region
of the 13 cardiac MHC gene. While none ofthe malignant FHC
mutations directly alter sequences that appear critical for bind-
ing ATP or myosin light chains, the recently published crystal
structure of the chicken skeletal muscle myosin head by Ray-
ment and colleagues (23) provides insight into the conse-
quences of one malignant mutation. The three-dimensional
structure revealed a loop formed by amino acid residue Arg
405 (corresponding to amino acid residue 403 in human) to
residue Lys 415, that interacts with actin. The Arg4O3Gln mu-
tation should alter loop structure and effect stereospecific inter-
actions between actin and myosin. The three-dimensional
structure of myosin combined with biochemical studies (24,
25) suggested a model for muscle contraction in which confor-
mational changes in myosin occur during ATP binding and
hydrolysis that disrupts actin binding. Actin and myosin re-
binding is hypothesized to be sequential and requires several
conformational states for myosin that produce stereospecific
interactions between these molecules. This model suggests that
the location ofa mutation and resultant changes in stoichiome-
try and charge may account for differing muscle function that
ultimately impact on survival. We speculate that malignant
mutations either impede conformational changes in myosin or
alter interactions with actin and other molecules. Less severe
phenotypes are expected from mutations that are either posi-
tioned in noncritical regions or that produce modest changes in
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(0) (+1) (0) (-1) (+1) (-1) (-1) (+ 1) (0) (+2) (+2)
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Figure 5. A schematic of mutations within the f cardiac MHC gene that cause FHC. Mutations that are previously described (Arg249Gln, 9;
Gly256Glu, 19; Arg4O3Gln, 6, 7, 15, 18, 20; Arg453Cys, 6; Gly584Arg, 6; Val606Met, 6; Lys615Asn, 21; Arg723Cys, 22; Gly74lArg, 19;
Leu9O8Val, 7, 16; Glu924Lys, 6; Glu949Lys, 6; deletion, 16) and reported here (Phe5 13Cys, Gly716Arg, Arg7l9Trp) are shown by a three-letter
code to denote the normal and mutated amino acid sequence. The change in charge resulting from each mutation is indicated. The letter B
(benign) denotes mutations associated with near normal life expectancy; M (malignant) denotes those which significantly reduce life expectancy;
I (intermediate) indicates mutations with a moderate effect on life expectancy. The transcription initiation signal (ATG) and regions that encode
the binding ofATP, actin, or the myosin light chain (MLC) are indicated. The globular head and rod segment of the ,B cardiac MHC polypeptide
are shown.
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changes in secondary structure. Alternatively, some mutations
may perturb a single myosin function, whereas other muta-
tions may alter several functions and result in a more severe
phenotype. Future studies that integrate genetic data, struc-
tural modeling, and biochemical studies should more fully elu-
cidate the mechanisms by which mutations perturb myosin
physiology and result in significant cardiac pathology.
Definition of the full spectrum of (3 cardiac MHC muta-
tions that cause the differing phenotypes found in FHC will
contribute to understanding myosin processes. Ultimately this
may help to improve therapeutics for the dysfunctional hyper-
trophic heart. More immediately, a compilation of the clinical
outcomes associated with different A cardiac MHC mutations
will enable physicians to recognize and treat those individuals
at risk for the serious sequelae of FHC.
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